Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL ANTI-RETROVIRAL DRUGS INDUSTRY
2.1 Summary about Anti-Retroviral Drugs Industry
2.2 Anti-Retroviral Drugs Market Trends
2.2.1 Anti-Retroviral Drugs Production & Consumption Trends
2.2.2 Anti-Retroviral Drugs Demand Structure Trends
2.3 Anti-Retroviral Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Protease Inhibitors
4.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors
4.2.3 Integrase Inhibitors
4.2.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hepatitis
4.3.2 HIV/AIDS
4.3.3 Herpes
4.3.4 Influenza
4.3.5 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Protease Inhibitors
5.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors
5.2.3 Integrase Inhibitors
5.2.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hepatitis
5.3.2 HIV/AIDS
5.3.3 Herpes
5.3.4 Influenza
5.3.5 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Protease Inhibitors
6.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors
6.2.3 Integrase Inhibitors
6.2.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hepatitis
6.3.2 HIV/AIDS
6.3.3 Herpes
6.3.4 Influenza
6.3.5 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Protease Inhibitors
7.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors
7.2.3 Integrase Inhibitors
7.2.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hepatitis
7.3.2 HIV/AIDS
7.3.3 Herpes
7.3.4 Influenza
7.3.5 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Protease Inhibitors
8.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors
8.2.3 Integrase Inhibitors
8.2.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hepatitis
8.3.2 HIV/AIDS
8.3.3 Herpes
8.3.4 Influenza
8.3.5 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Protease Inhibitors
9.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors
9.2.3 Integrase Inhibitors
9.2.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hepatitis
9.3.2 HIV/AIDS
9.3.3 Herpes
9.3.4 Influenza
9.3.5 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Cardionet
10.1.2 GE Healthcare
10.1.3 Abbott
10.1.4 AstraZeneca
10.1.5 Bristol-Myers-Squibb
10.1.6 Gilead
10.1.7 Cardiac Science Corp.
10.1.8 Cardiocom
10.1.9 Biotelemetry
10.1.10 GlaxoSmithKline
10.1.11 Roche
10.2 Anti-Retroviral Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Cardionet
10.2.2 GE Healthcare
10.2.3 Abbott
10.2.4 AstraZeneca
10.2.5 Bristol-Myers-Squibb
10.2.6 Gilead
10.2.7 Cardiac Science Corp.
10.2.8 Cardiocom
10.2.9 Biotelemetry
10.2.10 GlaxoSmithKline
10.2.11 Roche
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
